Jose Fernando Moura, PhD· @FernandoOnco · X·· 4 小时前评分70
正文 · 机器翻译
不断演变的 mEGFR 2+ 线治疗
两项试验，两种不同的 ADC 🇨🇳
Izalontamab-brengitecan 双特异性（HER3xEGFR），DAR 8
Ruzaltatug-rezetecan（HER3），DAR 4
PFS 显示出强劲信号
@myESMO #ESMO26
25 浏览 · 1 赞 · 0 转发 · 0 回复
会议摘要
Phase II study of izalontamab brengitecan (Iza-bren) plus osimertinib in patients with EGFR mutant locally advanced or metastatic non-small cell lung cancer (NSCLC)
https://esmocongress.esmo.orgLBA50按 Proffered paper 1: Breast cancer, early and advanced stage 对上
PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.org来源：Jose Fernando Moura, PhD · x.com